Oral chemo and targeted therapy before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests a combination of an oral chemotherapy pill (paclitaxel) with two targeted antibodies (pertuzumab and trastuzumab) given before surgery for HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-positive (a type that can be treated with targeted drugs).
- Your cancer has not spread to other parts of the body (stage M0).
- You have not had chemotherapy or targeted therapy for this breast cancer yet.
- Your heart, blood, liver, and kidney function are within safe limits (your doctor will check this).
- You are willing to take the study drugs by mouth and have no serious stomach or intestine problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral form of paclitaxel combined with standard HER2 therapy given before surgery for HER2-positive breast cancer. It aims to find the best dose and see how well it works.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This trial tests a treatment given before breast surgery to shrink breast cancer and improve outcomes based on your tumor type. Your eligibility depends on tumor size/stage, hormone and HER2 markers, and overall health checks.
This trial compares two anti-HER2 medicines given before surgery to shrink HER2-positive early breast cancer. It aims to see which treatment works better as “neoadjuvant” therapy to improve outcomes while keeping you safe.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
Hear when a new Breast Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.